Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hizentra for Infection Prophylaxis in CLL
NCT03730129Phase 3Completed
- Sponsor
- Rochester General Hospital
- Start
- Nov 2018
- Primary completion
- Jul 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of polyvalent human immunoglobulin in secondary immunodeficiency (SID), sponsored by Rochester General Hospital. Started Nov 2018; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
secondary immunodeficiency (SID)
Beyond the preview
Go deeper on NCT03730129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03730129.